Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma. The combination ...

Jan 12 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's (MRK.N), opens new tab blockbuster immunotherapy Keytruda in combination with ...

Consuming more sugar does not feed cancer cells, but the concern is that it does cause inflammation in the body if you're eating excess sugar in your diet. It is those inflammatory changes that are ...

MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

Keytruda is proving effective in treating more and more types of cancer, and its long-term growth potential is massive in my view. I believe Keytruda is set to generate $31 billion revenue by the end ...

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.